Annual report pursuant to Section 13 and 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

v3.23.1
License, Clinical Trial and Sponsored Research Agreements (Tables)
12 Months Ended
Dec. 31, 2022
License Agreements [Member]  
License, Clinical Trial and Sponsored Research Agreements  
Schedule of Clinical Trial and Sponsored Research Agreements

For the years ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for licenses acquired:

For the year ended December 31, 

($ in thousands)

    

2022

    

2021

City of Hope National Medical Center

CD123

$

$

250

IV/ICV

125

PSCA

250

HER2

200

CSL Behring (Calimmune)

40

30

Leiden University Medical Centre

350

Mayo Clinic

750

Fortress PIK Dividend

1,109

4,212

Total

$

1,474

$

5,842

Sponsored Research and Clinical Trial Agreements [Member]  
License, Clinical Trial and Sponsored Research Agreements  
Schedule of Clinical Trial and Sponsored Research Agreements

For the year ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

For the year ended December 31, 

($ in thousands)

    

2022

    

2021

City of Hope National Medical Center

$

$

CD123

166

301

IL13Rα2

1,486

1,169

CS1

482

608

HER2

784

697

PSCA

103

107

Fred Hutchinson Cancer Center - CD20

1,987

1,979

St. Jude Children's Research Hospital - XSCID

508

865

LUMC - RAG1 SCID

505

170

Mayo Clinic

968

695

Total

$

6,989

$

6,591